Lapatinib Ditosylate
Breast, Advance Directives, Postmenopause + 1 more
Treatment
6 FDA approvals
6 Active Studies for Lapatinib Ditosylate
Treatment for
Breast
What is Lapatinib Ditosylate
Lapatinib
The Generic name of this drug
Treatment Summary
Lapatinib is an anti-cancer medication developed by GlaxoSmithKline (GSK) to treat solid tumors such as breast and lung cancer. It was approved by the FDA in 2007 and is used in combination with the chemotherapy drug Capecitabine. Lapatinib works by blocking the activity of two proteins in the body, HER2/ERBB2 and HER1/EGFR/ERBB1. This prevents them from binding together, which helps stop the growth and spread of cancer cells.
Tykerb
is the brand name
Lapatinib Ditosylate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tykerb
Lapatinib
2007
3
Approved as Treatment by the FDA
Lapatinib, also called Tykerb, is approved by the FDA for 6 uses which include refractory, metastatic Breast cancer and Metastatic Breast Cancer .
refractory, metastatic Breast cancer
Used to treat refractory, metastatic Breast cancer in combination with Capecitabine
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with Letrozole
Breast
Used to treat refractory, metastatic Breast cancer in combination with Capecitabine
Postmenopause
Used to treat Postmenopausal in combination with Letrozole
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with Letrozole
Advance Directives
Used to treat refractory, advanced Breast cancer in combination with Capecitabine
Effectiveness
How Lapatinib Ditosylate Affects Patients
Lapatinib is a medication used to treat certain types of cancer, such as breast and lung cancer. It inhibits the growth of cancer cells by blocking certain proteins known as kinases. Developed by GlaxoSmithKline, the FDA approved lapatinib for use in advanced metastatic breast cancer in combination with capecitabine chemotherapy on March 13, 2007.
How Lapatinib Ditosylate works in the body
Lapatinib is a drug that works to stop cancer cells from growing. It works by targeting the tyrosine kinase domains of the epidermal growth factor receptor and human epidermal growth factor receptor, which are both associated with cancer. Studies have shown that Lapatinib is effective in stopping tumor cell growth in laboratory and animal models, and that it can be used in combination with other cancer medications for an even greater effect. Lapatinib also works well against cancer cells that have become resistant to other treatments.
When to interrupt dosage
The suggested amount of Lapatinib Ditosylate is contingent upon the recognized disorder, including Advance Directives, Postmenopause and Metastatic Breast Cancer. The quantity of dosage shifts, as per the approach of administration (e.g. Tablet - Oral or Oral) featured in the table beneath.
Condition
Dosage
Administration
Breast
, 250.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Advance Directives
, 250.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Postmenopause
, 250.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Metastatic Breast Cancer
, 250.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Warnings
There are 20 known major drug interactions with Lapatinib Ditosylate.
Common Lapatinib Ditosylate Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Lapatinib.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Lapatinib.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Lapatinib.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Lapatinib.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Lapatinib.
Lapatinib Ditosylate Toxicity & Overdose Risk
One patient who took 3,000 mg of lapatinib for 10 days had severe diarrhea and vomiting on the last day of treatment.
Lapatinib Ditosylate Novel Uses: Which Conditions Have a Clinical Trial Featuring Lapatinib Ditosylate?
78 active trials are currently in progress to assess the efficacy of Lapatinib Ditosylate in providing Advance Directives, Metastatic Breast Cancer and Breast related treatments.
Condition
Clinical Trials
Trial Phases
Postmenopause
5 Actively Recruiting
Phase 2, Not Applicable
Breast
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Lapatinib Ditosylate Reviews: What are patients saying about Lapatinib Ditosylate?
4
Patient Review
3/11/2011
Lapatinib Ditosylate for HER2 Positive Breast Cancer
3.3
Patient Review
4/9/2010
Lapatinib Ditosylate for HER2 Positive Breast Cancer
2.3
Patient Review
11/2/2010
Lapatinib Ditosylate for HER2 Positive Breast Cancer
1.7
Patient Review
3/24/2014
Lapatinib Ditosylate for Hormone Receptor Positive, HER2 Positive Metastatic Breast Cancer
Patient Q&A Section about lapatinib ditosylate
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is lapatinib used for?
"Lapatinib is used in conjunction with capecitabine to treat a certain type of advanced breast cancer in patients who have already received treatment with other chemotherapy drugs."
Answered by AI
What kind of inhibitor is lapatinib?
"Lapatinib is a drug taken orally that targets two proteins, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2). These proteins are often overexpressed in cancer."
Answered by AI
Is lapatinib FDA approved?
"The US Food and Drug Administration has approved Tykerb, in combination with capecitabine, as a treatment for patients with advanced or metastatic breast cancer who have overexpressed HER2 and have received prior therapies including an anthracycline, a taxane, and trastuzumab."
Answered by AI